Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$2.6 - $6.14 $130,000 - $307,000
-50,000 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$8.55 - $111.89 $427,500 - $5.59 Million
50,000 New
50,000 $489,000

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $103M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Murchinson Ltd. Portfolio

Follow Murchinson Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Murchinson Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Murchinson Ltd. with notifications on news.